PE anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
XMG1.2
PMA/Ionomycin-stimulated BALB/c T-cells were stained with CD3 FITC and XMG1.2 PE
  • XMG1.2
    PMA/Ionomycin-stimulated BALB/c T-cells were stained with CD3 FITC and XMG1.2 PE
See PE spectral data
Cat # Size Price Quantity Check Availability Save
505807 25 µg 28,00€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
505808 100 µg 80,00€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical data sheet

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-? (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-? (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-?-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-?. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-? bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-? in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  2. Koenecke C, et al. 2012. J Immunol. 189:2890. PubMed
  3. Ma Y, et al. 2013. J Immunol. 190:5588. PubMed
  4. Cho K, Hill A 2008. J Immunol Methods. 330:137. PubMed
  5. Wang H, et al. 2013. J Immunol. 191:6010. PubMed
  6. Gaylo A, et al. 2013. Transpl Immunol. 20:163. PubMed
  7. Dutow P, et al. 2014. J Infect Dis. 209:1269. PubMed
  8. Michel M, et al. 2012. Proc Natl Acad Sci U S A. 109:17459. PubMed
  9. Wan Y, et al. 2014. Vaccine. 41:241. PubMed
  10. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  11. Gungor B, et al. 2014. Sci Transl Med. 6:235. PubMed
  12. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  13. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  14. Sartorius R, et al. 2015. EMBO Mol Med. 7: 973 - 988. PubMed
  15. Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed
  16. Shami A, et al. 2015. Sci Rep. 5: 13904. PubMed
  17. Condotta S, et al. 2015. J Immunol. 195: 116 - 125. PubMed
  18. Sandrock I, et al. 2015. PLoS One. 10: 0145010. PubMed
  19. Ren Y, et al. 2015. Sci Rep. 5: 18099. PubMed
  20. QT N, et al. 2015. Antimicrob Agents Chemother. 59: 6308-6316. PubMed
  21. Kim K, et al. 2016. PLoS One. 11: 0148576. PubMed
  22. Su N, Xiong Y 2016. Sci Rep. 6:22658. PubMed
  23. Satoh M, et al. 2016. Sci Rep. 6:28473. PubMed
  24. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  25. Latasa C, et al. 2016. PLoS One. 11: 0161216. PubMed
  26. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  27. Castiglioni P, et al. 2017. PLoS Negl Trop Dis. 10.1371/journal.pntd.0005240. PubMed
  28. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  29. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  30. Tang Y, et al. 2020. Front Immunol. 11:585918. PubMed
  31. Hirata SI, et al. 2020. Allergy. 75:1939. PubMed
  32. Galeano Niño JL, et al. 2020. J Cell Sci. 133:00:00. PubMed
  33. Alissafi T, et al. 2020. Cell Metabolism. 32(4):591-604.e7. PubMed
  34. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  35. Gong Y, et al. 2020. Cell Metabolism. 33(1):51-64.e9. PubMed
  36. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  37. Koren N, et al. 2021. Cell Host Microbe. 29(2):197-209.e5. PubMed
  38. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
  39. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  40. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  41. Dong L, et al. 2021. Cancer Cell. . PubMed
  42. Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed
  43. Gálvez-Cancino F, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.041. PubMed
  44. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  45. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  46. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  47. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  48. Chen D, et al. 2018. Nat Commun. 9:873. PubMed
  49. Zhang J, et al. 2018. Nature. 553:91. PubMed
  50. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  51. Yan Y, et al. 2018. JCI Insight. 3. PubMed
  52. Marcus A et al. 2018. Immunity. 49(4):754-763 . PubMed
  53. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
  54. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  55. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  56. Bradley CP et al. 2017. Cell host & microbe. 22(5):697-704 . PubMed
  57. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  58. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
  59. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
  60. Chakrabarti J, et al. 2018. Oncotarget. 9:37439. PubMed
  61. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  62. Karandikar SH, et al. 2019. JCI Insight. 5. PubMed
  63. Leclerc M, et al. 2019. Nat Commun. 10:3345. PubMed
  64. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  65. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  66. Tomaru U et al. 2019. Cell reports. 26(3):639-651 . PubMed
  67. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  68. Tian D, et al. 2019. Nat Commun. 10:4246. PubMed
  69. Shi L, et al. 2019. Theranostics. 9:4115. PubMed
  70. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  71. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  72. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  73. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  74. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  75. Pan W et al. 2017. Immunity. 47(2):284-297 . PubMed
  76. Probst P, et al. 2017. Cancer Res. 77:3644. PubMed
  77. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  78. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  79. Wang X, et al. 2018. Int Immunopharmacol. 56:249. PubMed
  80. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  81. Roy S, et al. 2019. Front Immunol. 2.404166667. PubMed
  82. Lin W, et al. 2019. EBioMedicine. 49:133. PubMed
  83. Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
  84. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  85. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  86. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  87. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  88. Mandour MF, et al. 2020. Infect Agent Cancer. 15:30. PubMed
  89. Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed
  90. Hegde S, et al. 2020. Cancer Cell. 37(3):289-307. PubMed
  91. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  92. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  93. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  94. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  95. Kalafati L, et al. 2020. Cell. 183:771. PubMed
  96. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  97. Kraus Z, et al. 2008. J Immunol. 181:7800. PubMed
  98. Hundt M, et al. 2009. J Immunol. 183:1685. PubMed
RRID
AB_315401 (BioLegend Cat. No. 505807)
AB_315402 (BioLegend Cat. No. 505808)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 2    Revision Date: 12.11.2012

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Insert Note Here
Save Close Clear
Lab Timer
Tools
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account